Results 101 to 110 of about 3,235 (226)

Mucus Plugging as a Treatable Trait Across the Asthma–COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging

Biomedicines
Background: Airway mucus plugging is a key but long-overlooked mechanism of persistent airflow obstruction in both asthma and chronic obstructive pulmonary disease (COPD).
Pier-Valerio Mari, Alberto Ricci, Angelo Coppola, Davide Onofrio Fontana, David Selvaggio, Lorenzo Carriera, Simone Ielo, Matteo Siciliano, Loreta Di Michele, Veronica Ojetti   +9 more
doaj   +1 more source

Tezepelumab in near-fatal asthma requiring VV-ECMO

Respiratory Medicine Case Reports
Phase III studies have demonstrated that the anti-TSLP biologic tezepelumab significantly reduces asthma exacerbations in severe asthma, regardless of endotype. However, evidence on its use in near-fatal asthma is lacking. Tezepelumab's ability to reduce
Elisa Bentivegna, Greta Insalata, Luca Paita, Alessia Catalisano, Chiara Allegrini, Giovanni Cianchi, Manuela Bonizzoli, Federico Lavorini, Gianna Camiciottoli   +8 more
doaj   +1 more source

Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments

Journal of Asthma and Allergy, 2022
Laren D Tan,1,2 Nolan Nguyen,3 Abdullah Alismail,2 Mario Castro4 1Department of Internal Medicine, School of Medicine, Loma Linda University Health, Loma Linda, CA, USA; 2Department of Cardiopulmonary Sciences, School of Allied Health Professions, Loma ...
Tan LD, Nguyen N, Alismail A, Castro M
doaj  

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, reduced annualized asthma exacerbation rate (AAER) and improved lung function, asthma control, and health-related quality of life (HRQoL) in patients with ...
Xinyan Yang, Lihong Wang, Ke-Wu Huang, Wei Tang, E. Berame, Hae-sim Park, G. Hunter, Wei Jiang, C. Wu, C. W. Min, Katarzyna Domek-Zielinska, H. Lal, Nestor A. Molfino, S. Ponnarambil, N. Zhong   +14 more
semanticscholar   +1 more source

Tezepelumab-ekko

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses.

Annals of Allergy, Asthma & Immunology
BACKGROUND Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin (TSLP). In the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, tezepelumab reduced exacerbations and improved lung ...
W. Feleszko, M. Caminati, J. Gern, S. Johnston, C. Marchese, Deborah Clarke, Christopher S. Ambrose, Andrew W. Lindsley   +7 more
semanticscholar   +1 more source

Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice.

Allergologia et Immunopathologia
INTRODUCTION Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with ...
J. C. Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, F. Bravo-Gutiérrez, R. Andújar-Espinosa, M. Castilla-Martínez, C. Díaz-Chantar, S. Cabrejos-Perotti, J. Valverde-Molina, V. Pérez-Fernández, Re-Asgramur Group   +10 more
semanticscholar   +1 more source

Novel Real-World Insights Into Tezepelumab Effectiveness in Steroid-Dependent Asthma

Journal of Asthma and Allergy
A small yet significant subset (~4%) of severe asthma (SA) patients are dependent on daily maintenance aka chronic oral corticosteroids (OCS) to maintain asthma control.
M. Aslam, R. Senn, Amirbehzad Bagheri, H. Harwood, J. Troost, N. Lugogo, Arjun Mohan   +6 more
semanticscholar   +1 more source

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

COPD
Background Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.Methods We conducted a systematic review of ...
Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho   +6 more
doaj   +1 more source

Bucher indirect treatment comparison of phase 3 trials with dupilumab and tezepelumab in chronic rhinosinusitis with nasal polyps

Background: Biologic therapies significantly affect clinical outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNPs), including those with comorbid asthma.
Lipworth, Brian J., Greig, Robert, Suter, Philipp   +2 more
core   +1 more source